Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Markoczy, Zsolt; Sarosi, Veronika; Kudaba, Iveta; Galffy, Gabriella; Turay, Ulku; DEMİRKAZIK, AHMET; Purkalne, Gunta; Somfay, Attila; Papai-Szekely, Zsolt; Raso, Erzsebet; Ostoros, Gyula

doi:10.1186/s12885-018-4283-z

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Atıf İçin Kopyala

Markoczy Z., Sarosi V., Kudaba I., Galffy G., Turay U. Y., DEMİRKAZIK A., ...Daha Fazla

BMC CANCER, cilt.18, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18
Basım Tarihi: 2018
Doi Numarası: 10.1186/s12885-018-4283-z
Dergi Adı: BMC CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Non-small cell lung cancer, Lung adenocarcinoma, EGFR, Erlotinib, GROWTH-FACTOR RECEPTOR, TYROSINE KINASE INHIBITORS, 1ST-LINE TREATMENT, CIGARETTE-SMOKING, CANCER, CHEMOTHERAPY, SURVIVAL, GEFITINIB, GENE, RARE
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Background: Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine clinical setting is limited we conducted a multicenter, phase IV clinical trial to determine the efficacy and safety of erlotinib and to demonstrate the feasibility of the validated standardized companion diagnostic method of EGFR mutation detection.